Spots Global Cancer Trial Database for acute myeloid leukemia
Every month we try and update this database with for acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | NCT00728520 | Acute Myeloid L... Elderly | Azacitidine | 60 Years - | Kansas City Veteran Affairs Medical Center | |
| Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients | NCT00952588 | Acute Myeloid L... | AZD1152 LDAC | 60 Years - | AstraZeneca | |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | NCT03465540 | Multiple Myelom... Acute Myeloid L... Non-Hodgkins Ly... Myelodysplastic... AML MDS NHL | AMG 397 Dexamethasone Azacitidine | 18 Years - 65 Years | Amgen | |
| Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease | NCT04209712 | Acute Myeloid L... | haploid allogen... | 1 Year - 80 Years | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | |
| A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | NCT02842827 | Acute Myeloid L... Myelodysplastic... | bomedemstat tretinoin | 18 Years - | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | |
| Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma | NCT04460235 | Vaccine Streptococcus P... Acute Myeloid L... Lymphoma, Non-H... | Prevenar13 Pneu... | 18 Years - | Poitiers University Hospital | |
| Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | NCT01636609 | Acute Myeloid L... High Risk Myelo... | Azacitidine Cytarabine Tosedostat | 60 Years - | M.D. Anderson Cancer Center | |
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | NCT04669067 | Acute Myeloid L... | TL-895 KRT-232 | 18 Years - | Telios Pharma, Inc. | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03194685 | AML, Adult | FF-10101-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT01305499 | Acute Myeloid L... | Entinostat days... 5AC Entinostat days... | 60 Years - | Case Comprehensive Cancer Center | |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML | NCT04913922 | Acute Myeloid L... | Azacitidine Inj... Nivolumab Relatlimab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT03194685 | AML, Adult | FF-10101-01 | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | NCT01823198 | Accelerated Pha... Acute Erythroid... Acute Megakaryo... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Blast Phase Chr... Blasts Under 20... Blasts Under 20... Chronic Myelomo... High Risk Myelo... Myelodysplastic... Recurrent Chron... Therapy-Related... Therapy-Related... | Aldesleukin Allogeneic CD56... Allogeneic Hema... Busulfan Fludarabine Pho... Laboratory Biom... Peripheral Bloo... Pharmacological... | 7 Years - 65 Years | M.D. Anderson Cancer Center | |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | NCT02099266 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Hodgkins Lympho... Non-Hodgkins Ly... | Administration ... | 17 Years - 70 Years | University of Kansas Medical Center | |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | NCT05396859 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Decitabine and ... Entrectinib Laboratory Biom... | 18 Years - | OHSU Knight Cancer Institute | |
| Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | NCT00723099 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg... | Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... | - 69 Years | Fred Hutchinson Cancer Center | |
| Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia | NCT05983172 | Acute Myeloid L... | 18 Years - | National Taiwan University Hospital | ||
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | NCT05010772 | Acute Myeloid L... | Decitabine and ... Enasidenib Gilteritinib Ivosidenib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy | NCT05249894 | Acute Myeloid L... | 18 Years - 70 Years | Azienda Ospedaliera Città della Salute e della Scienza di Torino | ||
| Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML | NCT06110208 | Acute Myeloid L... | CLL1 and CD38 d... | 18 Years - 70 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | NCT04128501 | Acute Bilineal ... Acute Biphenoty... Acute Myeloid L... Mixed Phenotype... T Acute Lymphob... Therapy-Related... | Azacitidine Venetoclax | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | NCT06017258 | Refractory Acut... Relapsed Acute ... Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CD371-YSNVZ-IL1... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old | NCT02432911 | Acute Myeloid L... | CAG regimen (Ac... low dose cytara... | 65 Years - 75 Years | ChineseAMS | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT04789408 | Acute Myeloid L... | Cyclophosphamid... Fludarabine KITE-222 | 18 Years - | Gilead Sciences | |
| Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia | NCT01677949 | Acute Myeloid L... Acute Lymphobla... | Clofarabine Etoposide Cyclophosphamid... allogeneic hema... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome | NCT01311258 | Acute Myeloid L... Myelodysplastic... | 18 Years - | University of Rochester | ||
| Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital | NCT05558943 | Acute Myeloid L... | 18 Years - | Assistance Publique - Hôpitaux de Paris | ||
| Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | NCT01461538 | Acute Lymphoid ... Acute Myeloid L... Anemia, Refract... Solid Tumors | brentuximab ved... brentuximab ved... brentuximab ved... | 6 Years - | Seagen Inc. | |
| Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML | NCT01191801 | Acute Myeloid L... | vosaroxin + cyt... placebo + cytar... | 18 Years - | Sunesis Pharmaceuticals | |
| CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | NCT04156256 | Hematologic Mal... Acute Myeloid L... Myelodysplastic... Myeloproliferat... Chronic Myeloid... | CD123-CD33 cCAR... | - | iCell Gene Therapeutics | |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | NCT04964505 | Acute Myeloid L... | Azacitidine Uproleselan Venetoclax | 18 Years - | University of California, Davis | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) | NCT02101983 | Acute Myeloid L... | Cytosine Arabin... | 55 Years - 65 Years | University of Rochester | |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01238211 | Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Core Binding Fa... Secondary Acute... Therapy-Related... | Cytarabine Dasatinib Daunorubicin Hy... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | NCT01025778 | Acute Lymphobla... Acute Myeloid L... | Clofarabine for... Etoposide for r... Cyclophosphamid... Clofarabine in ... Thiotepa in con... Melfalan in con... Haploidentical ... Donor lymphocyt... | 1 Year - 21 Years | Lund University Hospital | |
| Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia | NCT04172844 | Acute Myelogeno... | Azacitidine Venetoclax Pevonedistat | 18 Years - | Medical College of Wisconsin | |
| A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML) | NCT04827069 | Acute Myeloid L... | Clifutinib Besy... | 18 Years - | Sunshine Lake Pharma Co., Ltd. | |
| Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA) | NCT06297551 | Acute Myeloid L... | Quantification ... | 18 Years - | Stony Brook University | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings | NCT04969601 | Acute Leukemia Acute Lymphobla... Acute Myeloid L... | vaccine COMIRNA... | 1 Year - 15 Years | Assistance Publique - Hôpitaux de Paris | |
| Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | NCT04070768 | Acute Myeloid L... | Gemtuzumab Ozog... Venetoclax | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | NCT05140811 | Acute Myeloid L... Myelodysplastic... | IMM01 Azacitidine | 18 Years - | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | NCT06197672 | Acute Myeloid L... | CD4CAR | 18 Years - | Indiana University | |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | NCT01943851 | Neoplasms | GSK525762 | 18 Years - | GlaxoSmithKline | |
| Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience. | NCT03350152 | Acute Myeloid L... | - | Hospices Civils de Lyon | ||
| Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | NCT00880243 | Acute Myeloid L... | GM-CSF | 15 Years - 50 Years | Acute Leukemia French Association | |
| Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma | NCT04460235 | Vaccine Streptococcus P... Acute Myeloid L... Lymphoma, Non-H... | Prevenar13 Pneu... | 18 Years - | Poitiers University Hospital | |
| Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2 | NCT03338348 | Acute Myeloid L... Myelodysplastic... | Vosaroxin Azacitidine | 60 Years - | University of Ulm | |
| Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT05961839 | Acute Myeloid L... High-Risk and V... | SGR-2921 | 18 Years - | Schrödinger, Inc. | |
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | NCT04097301 | Acute Myeloid L... Multiple Myelom... | MLM-CAR44.1 T-c... | 1 Year - 75 Years | AGC Biologics S.p.A. | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia | NCT03027102 | Acute Myeloid L... | DNT cells | 18 Years - | University Health Network, Toronto | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | NCT04980885 | Acute Myeloid L... | AK117 Azacitidine | 18 Years - | Akeso | |
| Removing Transfusion Dependence as a Barrier to Hospice Enrollment | NCT05063591 | Hematologic Mal... Myelodysplastic... Acute Myeloid L... Lymphoma Leukemia Myeloma | Transfusion sup... | 18 Years - | Brown University | |
| High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | NCT03178617 | Acute Lymphobla... Acute Myeloid L... Lymphoblastic L... Acute Leukemia | Educational Int... Educational Int... Quality-of-Life... Questionnaire A... | 5 Years - | City of Hope Medical Center | |
| Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies | NCT05588154 | Myelodysplastic... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | NCT04097301 | Acute Myeloid L... Multiple Myelom... | MLM-CAR44.1 T-c... | 1 Year - 75 Years | AGC Biologics S.p.A. | |
| Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia | NCT05000801 | Acute Myeloid L... | DC vaccine | 18 Years - 70 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML | NCT05703126 | Acute Myeloid L... Cardiotoxicity Endothelial Dys... | History taking Anthropometry Complete blood ... Biochemical blo... Coagulogram Immunoenzymatic... Stress echocard... Triplex scannin... Electrocardiogr... Ultrasound of t... Cytogenetic exa... Cytological exa... Immunophenotypi... Determination o... laser Doppler f... | 18 Years - 65 Years | Samara State Medical University | |
| Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML | NCT03642236 | FLT3-ITD Mutati... Acute Myeloid L... Brutons Tyrosin... | Ibrutinib | 14 Years - 60 Years | Nanfang Hospital, Southern Medical University | |
| An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) | NCT02775903 | Leukemia, Myelo... Myelodysplastic... | Azacitidine Durvalumab | 18 Years - | Celgene | |
| Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML | NCT01191957 | Acute Myeloid L... | Busulphan plus ... Busulphan plus ... | 40 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | NCT03055286 | Acute Myeloid L... | CWP232291 | 18 Years - | JW Pharmaceutical | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | NCT03417154 | Acute Myeloid L... Higher Risk Mye... | Nivolumab Low dose Cyclop... Low dose Cyclop... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML) | NCT02323022 | Acute Myeloid L... | IAC regimen IA regimen | 18 Years - 60 Years | The First Affiliated Hospital of Soochow University | |
| Long-term Outcomes for Acute Myeloid Leukemia Patients | NCT03755856 | Acute Myeloid L... | Questionnaire | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | NCT04589728 | Acute Myeloid L... | Venetoclax plus... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm | NCT06006403 | Acute Myeloid L... Blastic Plasmac... Relapse Leukemi... Refractory Leuk... | CD123 targeted ... | 18 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | NCT00990587 | Hematologic Mal... Acute Lymphocyt... Chronic Lymphoc... Myelodysplasia Acute Myeloid L... Chronic Myeloge... Hodgkin's Disea... | Ciclopirox Olam... | 18 Years - | University Health Network, Toronto | |
| Transfusional Iron Overload Among Leukemia Survivors | NCT01965171 | Acute Lymphocyt... Acute Myeloid L... | 5 Years - | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
